Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Antibiotics Play Novacta Wins £13.1 million, mostly from Celtic Pharma

This article was originally published in The Pink Sheet Daily

Executive Summary

Funds should allow Novacta Biosystems to take three peptide-based ‘lantibiotics' programs through to proof-of-efficacy and secure a licensing deal
Advertisement

Related Content

Biotech's Role In Rebuilding Big Pharma's Neglected Antibiotic Pipeline
Biotech's Role In Rebuilding Big Pharma's Neglected Antibiotic Pipeline
UK Biotech Proximagen Raises Record $80 Million ‘Asset Acquisition’ Fund
UK Biotech Proximagen Raises Record $80 Million ‘Asset Acquisition’ Fund
Basilea Takes On Partner J&J In Arbitration Claim Over Ceftobiprole Delays
The Antibiotic Drought Of 2008: Plenty Of Action But No NME Approvals
Industry’s Lesson On Non-Inferiority Margins In Anti-Infective Trials: Use 10%
Asset-Focused Funding

Topics

Advertisement
UsernamePublicRestriction

Register

PS069794

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel